Affiliation: 1 Medical Oncology Department, Hospital Clnic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Institut dInvestigacions Biomdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain ORCID: Affiliation: 1 Medical Oncology Department, Hospital Clnic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Institut dInvestigacions Biomdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain 2 CIBEREHD, Network Centre for Hepatic and Digestive Diseases, National Spanish Health Institute Carlos III (ISCIII), 28029 Madrid, Spain 3 Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08036 Barcelona, Spain ORCID: Affiliation: 3 Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08036 Barcelona, Spain ORCID: Affiliation: 1 Medical Oncology Department, Hospital Clnic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Institut dInvestigacions Biomdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain Affiliation: 1 Medical Oncology Department, Hospital Clnic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Institut dInvestigacions Biomdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain Affiliation: 2 CIBEREHD, Network Centre for Hepatic and Digestive Diseases, National Spanish Health Institute Carlos III (ISCIII), 28029 Madrid, Spain 3 Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08036 Barcelona, Spain ORCID: Affiliation: 2 CIBEREHD, Network Centre for Hepatic and Digestive Diseases, National Spanish Health Institute Carlos III (ISCIII), 28029 Madrid, Spain 3 Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08036 Barcelona, Spain Email: [email protected] ORCID: Affiliation: 1 Medical Oncology Department, Hospital Clnic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Institut dInvestigacions Biomdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain 2 CIBEREHD, Network Centre for Hepatic and Digestive Diseases, National Spanish Health Institute Carlos III (ISCIII), 28029 Madrid, Spain Email: [email protected] ORCID: Explor Target Antitumor Ther
A system transport present in the inner mitochondrial membrane, that involves dicarboxylate and 2-oxoglutarate anion transporters, allows the passage of negatively charged GSH from the cytosol to the mitochondria
(2017) 30:e12464
Largest reductions (18-20%) occurred in the high-dose group after 1 and 2 weeks Combined dose groups significantly reduced the ratio by 14% after 1 and 2 weeks The decreases observed in oxidized:reduced GSH as a result of oral liposomal GSH supplementation are likely indicative of a general systemic reduction in oxidative stress levels. Plasma levels of 8-isoprostane (a marker of oxidative stress) decreased after liposomal glutathione supplementation
